| Title: |
Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group |
| Authors: |
Floyd, JS; Sitlani, CM; Avery, CL; Noordam, R; Li, X; Smith, AV; Gogarten, SM; Li, J; Broer, L; Evans, DS; Trompet, S; Brody, JA; Stewart, JD; Eicher, JD; Seyerle, AA; Roach, J; Lange, LA; Lin, HJ; Kors, JA; Harris, TB; Li-Gao, R; Sattar, N; Cummings, SR; Wiggins, KL; Napier, MD; Stürmer, T; Bis, JC; Kerr, KF; Uitterlinden, AG; Taylor, KD; Stott, DJ; de Mutsert, R; Launer, LJ; Busch, EL; Méndez-Giráldez, R; Sotoodehnia, N; Soliman, EZ; Li, Y; Duan, Q; Rosendaal, FR; Slagboom, PE; Wilhelmsen, KC; Reiner, AP; Chen, Y-DI; Heckbert, SR; Kaplan, RC; Rice, KM; Jukema, JW; Johnson, AD; Liu, Y; Mook-Kanamori, DO; Gudnason, V; Wilson, JG; Rotter, JI; Laurie, CC; Psaty, BM; Whitsel, EA; Cupples, LA; Stricker, BH |
| Source: |
The Pharmacogenomics Journal, vol 18, iss 1 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2018 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
3214 Pharmacology and Pharmaceutical Sciences (for-2020); 32 Biomedical and Clinical Sciences (for-2020); Genetics (rcdc); Cardiovascular (rcdc); Prevention (rcdc); Human Genome (rcdc); Patient Safety (rcdc); Heart Disease (rcdc); Cardiovascular (hrcs-hc); 3 Good Health and Well Being (sdg); Aged (mesh); Cardiovascular Diseases (mesh); Cytochrome P-450 CYP2C9 (mesh); Diabetes Mellitus; Type 2 (mesh); Drug-Related Side Effects and Adverse Reactions (mesh); Electrocardiography (mesh); Ethnicity (mesh); Female (mesh); Genetic Variation (mesh); Genome-Wide Association Study (mesh); Humans (mesh); Male (mesh); Middle Aged (mesh); Pharmacogenetics (mesh); Pharmacogenomic Testing (mesh); Sulfonylurea Compounds (mesh) |
| Subject Geographic: |
127 - 135 |
| Description: |
Sulfonylureas, a commonly used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In 11 ethnically diverse cohorts that included 71 857 European, African-American and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT and QRS intervals. In ancestry-specific meta-analyses, eight novel pharmacogenomic loci met the threshold for genome-wide significance (P |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt12f2j929; https://escholarship.org/uc/item/12f2j929; https://escholarship.org/content/qt12f2j929/qt12f2j929.pdf |
| DOI: |
10.1038/tpj.2016.90 |
| Availability: |
https://escholarship.org/uc/item/12f2j929; https://escholarship.org/content/qt12f2j929/qt12f2j929.pdf; https://doi.org/10.1038/tpj.2016.90 |
| Rights: |
public |
| Accession Number: |
edsbas.9C7593DB |
| Database: |
BASE |